莱美药业：公司委托外部机构研发的玛巴洛沙韦片项目已于2025年6月获得伦理批件

Core Viewpoint - The company has received ethical approval for the development of Mabalosavir tablets, which is expected to advance clinical trials in accordance with national regulations by June 2025 [1] Group 1 - The company has commissioned an external organization to develop the Mabalosavir tablet project [1] - The clinical trials for Mabalosavir tablets will be conducted in an orderly manner following national clinical trial regulations [1] - The company will continue to monitor the progress of the Mabalosavir tablet clinical trials and fulfill information disclosure obligations as required [1]